Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Powassan Virus Diagnosed in Patients with Tick-Borne Diseases

By LabMedica International staff writers
Posted on 02 Aug 2017
Powassan virus (POWV) lineage II, also known as deer tick virus, is an emerging tick-borne flavivirus transmitted by Ixodes scapularis ticks, which are also the primary vector for the Lyme disease pathogen Borrelia burgdorferi.

The seroprevalence of POWV in humans in some regions of North America is known with a range of 0.5% to 3.3%, but because the geographic distribution is quite extensive, the seroprevalence of most at-risk populations is uncertain. More...
POWV is typically detected with an immunoglobulin M (IgM) antibody capture e enzyme-linked immunosorbent assay (ELISA) or an IgM immunofluorescence antibody (IFA) assay.

Scientists at the Marshfield Clinic Research Foundation (Minocqua, WI, USA) and their colleagues selected 95patients with suspected tick-borne disease (TBD) and 50 patients undergoing routine chemical screening who sought treatment during July to August 2015 at the Marshfield Clinic in northern Wisconsin, a TBD-endemic area. Patients were considered to have suspected TBD if a serologic test for B. burgdorferi was ordered.

The investigators performed screening assays on all specimens for tick-borne encephalitis virus complex (TBEV-C) and B. burgdorferi and performed POWV serology on TBEV-C–positive specimens. They evaluated heterologous flavivirus cross-reactivity, by performing the West Nile virus (WNV) enzyme immunoassay with TBEV-C–positive samples. They also performed the EUROIMMUN Flavivirus Mosaic Panel, an IgG IFA assay panel including tests for TBEV, WNV, yellow fever virus, dengue viruses 1–4, and Japanese encephalitis virus, on samples positive for POWV IgG by the IFA assay.

Serologic evidence of POWV infection was present in nine (9.5%) TBD patients and two (4.0%) patients with routine chemistry screening completed. Similar to other flavivirus serologic assays, considerable cross-reactivity occurred with the Flavivirus Mosaic IgG IFA assay. The fluorescence intensity was stronger for TBEV than it was for other flaviviruses in all TBD patients except for one patient with prior confirmed WNV infection. Evidence of current or prior B. burgdorferi infection was present in 63 (66.3%) TBD patients. Of the 41 (43.2%) TBD patients with evidence of B. burgdorferi infection, seven (17.1%) had serologic evidence of acute POWV infection and three (7.3%) had laboratory-confirmed POWV infection.

The authors concluded that in a Lyme disease–endemic area, POWV seroreactivity and confirmed POWV infection were present. The spectrum of disease is broader than previously realized, with most patients having minimally symptomatic infection. The study was published in the August 2017 issue of the journal Emerging Infectious Diseases.

Related Links:
Marshfield Clinic Research Foundation



Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.